Circulation:肺动脉高压-右心衰的新生物标志物——长链非编码RNA H19!

2020-10-16 MedSci原创 MedSci原创

右心室(RV)功能是肺动脉高压(PAH)患者心脏功能和生存能力的主要决定因素。尽管已经认识到了保留RV功能的临床重要性,调控从代偿状态到失代偿状态过渡的亚细胞机制仍然知之甚少,使得目前尚无针对RV衰竭

右心室(RV)功能是肺动脉高压(PAH)患者心脏功能和生存能力的主要决定因素。尽管已经认识到了保留RV功能的临床重要性,调控从代偿状态到失代偿状态过渡的亚细胞机制仍然知之甚少,使得目前尚无针对RV衰竭的临床治疗方法,也缺乏临床上有用的生物标记物。越来越多的证据表明,长链非编码RNA是心脏发育和疾病发生的重要调节因子。但是,它们在PAH中RV重构中的作用尚不清楚。

三种个体(CTRL、cRV、CTRL)心肌组织的纤维化和心肌肥大形态

Omura等人根据临床病史和心脏指数,通过定量PCR评估了RV代偿期(cRV)和RV失代偿期(dRV)的PAH患者以及健康对照(CTRL)的血浆和RV中长链非编码RNA H19的表达。并在模拟RV衰竭的2种大鼠模型中研究GapmeR抑制H19后的效应。

H19在三种个体(CTRL、cRV、CTRL)中的表达水平

研究发现,H19在RV失代偿期的PAH患者中表达上调,并与RV肥大和纤维化相关。在两种RV衰竭的大鼠模型中具有类似的结果。

抑制H19可改善大鼠模型的RV功能和存活预后

沉默H19表达可限制病理性RV肥大、纤维化和毛细血管稀疏,从而保持RV衰竭大鼠模型的RV功能,但不影响肺血管重构。这种心脏保护作用伴随着E2F转录因子1介导的zeste同源物2增强子的上调。

抑制H19或过表达H19对心肌肥大的影响

在体外,敲除H19可抑制去氧肾上腺素引起的心肌肥大,而其过表达则表现为相反的效应。

H19水平与IPAH患者预后相关

最后,研究人员证明了通过血浆H19水平可将PAH患者与对照组区别开来,与RV功能相关,并预测了2个独立的特发性PAH队列的长期生存预后。此外,与NT-proBNP或风险评分联合使用时,H19水平还可划分预后不同的患者亚组。

总之,该研究结果表明,H19是PAH的新的治疗靶标,可抑制适应不良的RV重构的进展,并可作为PAH严重程度和预后的有前途的生物标志物

原始出处:

Junichi Omura, et al. Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension. Circulation. 2020;142:1464–1484



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1925347, encodeId=745c192534ea6, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Apr 25 15:43:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959656, encodeId=afe695965687, content=这个是不是可以研究下, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8805421459, createdName=ms7000001807525455, createdTime=Fri Apr 23 07:26:05 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743522, encodeId=c5081e435222d, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Aug 01 18:43:58 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841587, encodeId=dc96184158e89, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 08 10:43:58 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894796, encodeId=d628894e96a4, content=H19是PAH的新的治疗靶标,可抑制适应不良的RV重构的进展,并可作为PAH严重程度和预后的有前途的生物标志物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Tue Oct 27 11:01:35 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937713, encodeId=1353193e713dd, content=<a href='/topic/show?id=562738645ec' target=_blank style='color:#2F92EE;'>#右心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38645, encryptionId=562738645ec, topicName=右心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Mar 14 07:43:58 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649718, encodeId=7db11649e18fe, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 20 06:43:58 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893332, encodeId=d2838933325e, content=右心室(RV)功能是肺动脉高压(PAH)患者心脏功能和生存能力的主要决定因素。尽管已经认识到了保留RV功能的临床重要性,调控从代偿状态到失代偿状态过渡的亚细胞机制仍然知之甚少,使得目前尚无针对RV衰竭, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Oct 20 16:57:34 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485844, encodeId=74d014858442e, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560965, encodeId=45f11560965f6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1925347, encodeId=745c192534ea6, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Apr 25 15:43:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959656, encodeId=afe695965687, content=这个是不是可以研究下, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8805421459, createdName=ms7000001807525455, createdTime=Fri Apr 23 07:26:05 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743522, encodeId=c5081e435222d, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Aug 01 18:43:58 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841587, encodeId=dc96184158e89, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 08 10:43:58 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894796, encodeId=d628894e96a4, content=H19是PAH的新的治疗靶标,可抑制适应不良的RV重构的进展,并可作为PAH严重程度和预后的有前途的生物标志物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Tue Oct 27 11:01:35 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937713, encodeId=1353193e713dd, content=<a href='/topic/show?id=562738645ec' target=_blank style='color:#2F92EE;'>#右心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38645, encryptionId=562738645ec, topicName=右心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Mar 14 07:43:58 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649718, encodeId=7db11649e18fe, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 20 06:43:58 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893332, encodeId=d2838933325e, content=右心室(RV)功能是肺动脉高压(PAH)患者心脏功能和生存能力的主要决定因素。尽管已经认识到了保留RV功能的临床重要性,调控从代偿状态到失代偿状态过渡的亚细胞机制仍然知之甚少,使得目前尚无针对RV衰竭, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Oct 20 16:57:34 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485844, encodeId=74d014858442e, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560965, encodeId=45f11560965f6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
    2021-04-23 ms7000001807525455

    这个是不是可以研究下

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1925347, encodeId=745c192534ea6, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Apr 25 15:43:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959656, encodeId=afe695965687, content=这个是不是可以研究下, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8805421459, createdName=ms7000001807525455, createdTime=Fri Apr 23 07:26:05 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743522, encodeId=c5081e435222d, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Aug 01 18:43:58 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841587, encodeId=dc96184158e89, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 08 10:43:58 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894796, encodeId=d628894e96a4, content=H19是PAH的新的治疗靶标,可抑制适应不良的RV重构的进展,并可作为PAH严重程度和预后的有前途的生物标志物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Tue Oct 27 11:01:35 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937713, encodeId=1353193e713dd, content=<a href='/topic/show?id=562738645ec' target=_blank style='color:#2F92EE;'>#右心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38645, encryptionId=562738645ec, topicName=右心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Mar 14 07:43:58 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649718, encodeId=7db11649e18fe, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 20 06:43:58 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893332, encodeId=d2838933325e, content=右心室(RV)功能是肺动脉高压(PAH)患者心脏功能和生存能力的主要决定因素。尽管已经认识到了保留RV功能的临床重要性,调控从代偿状态到失代偿状态过渡的亚细胞机制仍然知之甚少,使得目前尚无针对RV衰竭, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Oct 20 16:57:34 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485844, encodeId=74d014858442e, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560965, encodeId=45f11560965f6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
    2021-08-01 d830384
  4. [GetPortalCommentsPageByObjectIdResponse(id=1925347, encodeId=745c192534ea6, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Apr 25 15:43:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959656, encodeId=afe695965687, content=这个是不是可以研究下, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8805421459, createdName=ms7000001807525455, createdTime=Fri Apr 23 07:26:05 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743522, encodeId=c5081e435222d, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Aug 01 18:43:58 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841587, encodeId=dc96184158e89, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 08 10:43:58 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894796, encodeId=d628894e96a4, content=H19是PAH的新的治疗靶标,可抑制适应不良的RV重构的进展,并可作为PAH严重程度和预后的有前途的生物标志物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Tue Oct 27 11:01:35 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937713, encodeId=1353193e713dd, content=<a href='/topic/show?id=562738645ec' target=_blank style='color:#2F92EE;'>#右心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38645, encryptionId=562738645ec, topicName=右心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Mar 14 07:43:58 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649718, encodeId=7db11649e18fe, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 20 06:43:58 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893332, encodeId=d2838933325e, content=右心室(RV)功能是肺动脉高压(PAH)患者心脏功能和生存能力的主要决定因素。尽管已经认识到了保留RV功能的临床重要性,调控从代偿状态到失代偿状态过渡的亚细胞机制仍然知之甚少,使得目前尚无针对RV衰竭, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Oct 20 16:57:34 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485844, encodeId=74d014858442e, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560965, encodeId=45f11560965f6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1925347, encodeId=745c192534ea6, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Apr 25 15:43:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959656, encodeId=afe695965687, content=这个是不是可以研究下, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8805421459, createdName=ms7000001807525455, createdTime=Fri Apr 23 07:26:05 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743522, encodeId=c5081e435222d, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Aug 01 18:43:58 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841587, encodeId=dc96184158e89, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 08 10:43:58 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894796, encodeId=d628894e96a4, content=H19是PAH的新的治疗靶标,可抑制适应不良的RV重构的进展,并可作为PAH严重程度和预后的有前途的生物标志物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Tue Oct 27 11:01:35 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937713, encodeId=1353193e713dd, content=<a href='/topic/show?id=562738645ec' target=_blank style='color:#2F92EE;'>#右心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38645, encryptionId=562738645ec, topicName=右心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Mar 14 07:43:58 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649718, encodeId=7db11649e18fe, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 20 06:43:58 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893332, encodeId=d2838933325e, content=右心室(RV)功能是肺动脉高压(PAH)患者心脏功能和生存能力的主要决定因素。尽管已经认识到了保留RV功能的临床重要性,调控从代偿状态到失代偿状态过渡的亚细胞机制仍然知之甚少,使得目前尚无针对RV衰竭, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Oct 20 16:57:34 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485844, encodeId=74d014858442e, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560965, encodeId=45f11560965f6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
    2020-10-27 Lexi

    H19是PAH的新的治疗靶标,可抑制适应不良的RV重构的进展,并可作为PAH严重程度和预后的有前途的生物标志物。

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1925347, encodeId=745c192534ea6, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Apr 25 15:43:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959656, encodeId=afe695965687, content=这个是不是可以研究下, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8805421459, createdName=ms7000001807525455, createdTime=Fri Apr 23 07:26:05 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743522, encodeId=c5081e435222d, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Aug 01 18:43:58 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841587, encodeId=dc96184158e89, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 08 10:43:58 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894796, encodeId=d628894e96a4, content=H19是PAH的新的治疗靶标,可抑制适应不良的RV重构的进展,并可作为PAH严重程度和预后的有前途的生物标志物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Tue Oct 27 11:01:35 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937713, encodeId=1353193e713dd, content=<a href='/topic/show?id=562738645ec' target=_blank style='color:#2F92EE;'>#右心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38645, encryptionId=562738645ec, topicName=右心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Mar 14 07:43:58 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649718, encodeId=7db11649e18fe, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 20 06:43:58 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893332, encodeId=d2838933325e, content=右心室(RV)功能是肺动脉高压(PAH)患者心脏功能和生存能力的主要决定因素。尽管已经认识到了保留RV功能的临床重要性,调控从代偿状态到失代偿状态过渡的亚细胞机制仍然知之甚少,使得目前尚无针对RV衰竭, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Oct 20 16:57:34 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485844, encodeId=74d014858442e, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560965, encodeId=45f11560965f6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1925347, encodeId=745c192534ea6, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Apr 25 15:43:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959656, encodeId=afe695965687, content=这个是不是可以研究下, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8805421459, createdName=ms7000001807525455, createdTime=Fri Apr 23 07:26:05 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743522, encodeId=c5081e435222d, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Aug 01 18:43:58 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841587, encodeId=dc96184158e89, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 08 10:43:58 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894796, encodeId=d628894e96a4, content=H19是PAH的新的治疗靶标,可抑制适应不良的RV重构的进展,并可作为PAH严重程度和预后的有前途的生物标志物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Tue Oct 27 11:01:35 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937713, encodeId=1353193e713dd, content=<a href='/topic/show?id=562738645ec' target=_blank style='color:#2F92EE;'>#右心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38645, encryptionId=562738645ec, topicName=右心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Mar 14 07:43:58 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649718, encodeId=7db11649e18fe, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 20 06:43:58 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893332, encodeId=d2838933325e, content=右心室(RV)功能是肺动脉高压(PAH)患者心脏功能和生存能力的主要决定因素。尽管已经认识到了保留RV功能的临床重要性,调控从代偿状态到失代偿状态过渡的亚细胞机制仍然知之甚少,使得目前尚无针对RV衰竭, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Oct 20 16:57:34 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485844, encodeId=74d014858442e, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560965, encodeId=45f11560965f6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
    2021-01-20 tidiq
  8. [GetPortalCommentsPageByObjectIdResponse(id=1925347, encodeId=745c192534ea6, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Apr 25 15:43:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959656, encodeId=afe695965687, content=这个是不是可以研究下, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8805421459, createdName=ms7000001807525455, createdTime=Fri Apr 23 07:26:05 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743522, encodeId=c5081e435222d, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Aug 01 18:43:58 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841587, encodeId=dc96184158e89, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 08 10:43:58 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894796, encodeId=d628894e96a4, content=H19是PAH的新的治疗靶标,可抑制适应不良的RV重构的进展,并可作为PAH严重程度和预后的有前途的生物标志物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Tue Oct 27 11:01:35 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937713, encodeId=1353193e713dd, content=<a href='/topic/show?id=562738645ec' target=_blank style='color:#2F92EE;'>#右心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38645, encryptionId=562738645ec, topicName=右心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Mar 14 07:43:58 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649718, encodeId=7db11649e18fe, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 20 06:43:58 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893332, encodeId=d2838933325e, content=右心室(RV)功能是肺动脉高压(PAH)患者心脏功能和生存能力的主要决定因素。尽管已经认识到了保留RV功能的临床重要性,调控从代偿状态到失代偿状态过渡的亚细胞机制仍然知之甚少,使得目前尚无针对RV衰竭, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Oct 20 16:57:34 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485844, encodeId=74d014858442e, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560965, encodeId=45f11560965f6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
    2020-10-20 咻凡

    右心室(RV)功能是肺动脉高压(PAH)患者心脏功能和生存能力的主要决定因素。尽管已经认识到了保留RV功能的临床重要性,调控从代偿状态到失代偿状态过渡的亚细胞机制仍然知之甚少,使得目前尚无针对RV衰竭

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1925347, encodeId=745c192534ea6, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Apr 25 15:43:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959656, encodeId=afe695965687, content=这个是不是可以研究下, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8805421459, createdName=ms7000001807525455, createdTime=Fri Apr 23 07:26:05 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743522, encodeId=c5081e435222d, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Aug 01 18:43:58 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841587, encodeId=dc96184158e89, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 08 10:43:58 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894796, encodeId=d628894e96a4, content=H19是PAH的新的治疗靶标,可抑制适应不良的RV重构的进展,并可作为PAH严重程度和预后的有前途的生物标志物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Tue Oct 27 11:01:35 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937713, encodeId=1353193e713dd, content=<a href='/topic/show?id=562738645ec' target=_blank style='color:#2F92EE;'>#右心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38645, encryptionId=562738645ec, topicName=右心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Mar 14 07:43:58 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649718, encodeId=7db11649e18fe, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 20 06:43:58 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893332, encodeId=d2838933325e, content=右心室(RV)功能是肺动脉高压(PAH)患者心脏功能和生存能力的主要决定因素。尽管已经认识到了保留RV功能的临床重要性,调控从代偿状态到失代偿状态过渡的亚细胞机制仍然知之甚少,使得目前尚无针对RV衰竭, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Oct 20 16:57:34 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485844, encodeId=74d014858442e, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560965, encodeId=45f11560965f6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1925347, encodeId=745c192534ea6, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Sun Apr 25 15:43:58 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=959656, encodeId=afe695965687, content=这个是不是可以研究下, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8805421459, createdName=ms7000001807525455, createdTime=Fri Apr 23 07:26:05 CST 2021, time=2021-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1743522, encodeId=c5081e435222d, content=<a href='/topic/show?id=369199618db' target=_blank style='color:#2F92EE;'>#非编码#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99618, encryptionId=369199618db, topicName=非编码)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d435134939, createdName=d830384, createdTime=Sun Aug 01 18:43:58 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841587, encodeId=dc96184158e89, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 08 10:43:58 CST 2021, time=2021-05-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894796, encodeId=d628894e96a4, content=H19是PAH的新的治疗靶标,可抑制适应不良的RV重构的进展,并可作为PAH严重程度和预后的有前途的生物标志物。, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae205385871, createdName=Lexi, createdTime=Tue Oct 27 11:01:35 CST 2020, time=2020-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937713, encodeId=1353193e713dd, content=<a href='/topic/show?id=562738645ec' target=_blank style='color:#2F92EE;'>#右心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38645, encryptionId=562738645ec, topicName=右心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Sun Mar 14 07:43:58 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649718, encodeId=7db11649e18fe, content=<a href='/topic/show?id=029983e24d' target=_blank style='color:#2F92EE;'>#H19#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8372, encryptionId=029983e24d, topicName=H19)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85b723898983, createdName=tidiq, createdTime=Wed Jan 20 06:43:58 CST 2021, time=2021-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893332, encodeId=d2838933325e, content=右心室(RV)功能是肺动脉高压(PAH)患者心脏功能和生存能力的主要决定因素。尽管已经认识到了保留RV功能的临床重要性,调控从代偿状态到失代偿状态过渡的亚细胞机制仍然知之甚少,使得目前尚无针对RV衰竭, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Tue Oct 20 16:57:34 CST 2020, time=2020-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1485844, encodeId=74d014858442e, content=<a href='/topic/show?id=d0f29e089a9' target=_blank style='color:#2F92EE;'>#长链非编码RNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97089, encryptionId=d0f29e089a9, topicName=长链非编码RNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5df38055979, createdName=minhuang75_72521586, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560965, encodeId=45f11560965f6, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Sun Oct 18 09:43:58 CST 2020, time=2020-10-18, status=1, ipAttribution=)]

相关资讯

Nat Commun:汪永孝团队揭示肺动脉高压发病机制和潜在的新靶点

肺动脉高压是一种高致死性疾病。各种肺部疾病,包括慢性阻塞性肺病,高原性肺病和间质性肺病等,都可能在终末期导致肺动脉高压。肺动脉高压一旦出现,患者生存时间短,无特效药物,且生活质量严重下降。

Chest:肾素-血管紧张素-醛固酮系统抑制剂在肺动脉高压中的使用和对死亡率的影响

使用ACEI/ARB与PH患者较低的死亡率相关。使用AA是PH患者疾病严重程度的标志。ACEIs/ARBs可能是多种PH表型的治疗策略。

Sci Rep:中国很大肺移植中心的小儿肺移植

对于IPAH患儿,肺移植是一种安全的治疗方法,可以提高其寿命和生活质量,而ECMO有助于降低手术风险和术后并发症。

Hypertension:肺动脉顺应性对系统性红斑狼疮合并肺动脉高压患者的预测价值

肺动脉高压是系统性红斑狼疮严重的并发症,其特点是右心室后负荷增加,主要包括肺动脉顺应性(PAC)和肺血管阻力。PAC在预测系统性红斑狼疮相关的肺动脉高压预后中的作用尚未明确。

Circulation:MDM2介导的ACE2泛素化促进肺动脉高压进展

ACE2在Ser-680和Lys-788位点上的不适当翻译后修饰(磷酸化和泛素化)与肺动脉高压和实验性PH的发病机理有关。联合干预肺内皮细胞的AMPK和MDM2可能在PH治疗中具有一定疗效。

Clin Transl Med:CD248,可能是肺动脉高压的新治疗靶点

肺动脉重塑是肺动脉高压(PAH)最重要的临床病理改变。PAH的主要表现是肺动脉平滑肌细胞(PASMCs)功能异常,导致肺动脉中层增厚和表型改变,进而动脉梗阻逐渐加重和出现右心室肥厚。据估计目前PAH在